Sandra Horschitz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sandra Horschitz has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Philipp Koch
Department of Translational Brain Research, Central Institute of Mental Health (ZI), University of Heidelberg/ Medical Faculty Mannheim
21 shared publications - Dirk C. Hoffmann
Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany
20 shared publications - Ammar Jabali
Central Institute of Mental Health, University of Heidelberg/Medical Faculty Mannheim, Mannheim, Germany
19 shared publications - Daniel D. Azorin
Heidelberg University Medical Faculty, Neurology Clinic and European Center for Neurooncology (EZN), University Hospital Heidelberg, Heidelberg, Germany, and National Center for Tumor Diseases, Heidelberg, Germany.
19 shared publications - David Hausmann
Heidelberg University Medical Faculty, Neurology Clinic and European Center for Neurooncology (EZN), University Hospital Heidelberg, Heidelberg, Germany, and National Center for Tumor Diseases, Heidelberg, Germany.
19 shared publications - Frank Winkler
Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany
19 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by Springer Nature in Cellular and Molecular Bioengineering
- p. 1-15
Mocetinostat Shows Network-Inhibitory Effects on Glioblastoma Cells, Enhancing Radiotherapy Efficacy
Purpose: Glioblastoma cells use neurite-like extensions, called tumor microtubes (TMs), as intercellular connections to integrate into a communicating network that contributes to glioblastoma’s high therapy resistance. Understanding the biological functions of tumor cell connectivity and overcoming network resistance has emerged as a new therapeutic opportunity. We tested histone deacetylase inhibitors (HDACi) regarding their potential to overcome TM-mediated connectivity and resistance to therapy in glioblastoma. Methods: To investigate HDACi, we applied a recently established drug testing pipeline consisting of mono- and co-culture of primary glioblastoma cells in vitro with simplified brain organoids readouts of TM parameters and tumor cell viability. Next, the effect of the class I HDACi mocetinostat in our in vivo two-photon microscopy model with radiotherapy as cytotoxic co-treatment was investigated. To understand underlaying molecular mechanisms, bulk RNA sequencing was performed. Results: Mocetinostat showed dose-dependent anti-TM effects in vitro , in contrast to other classes of HDACi in monoculture. In a co-culture of glioblastoma cells with cortical spheroids from human induced pluripotent stem cells, mocetinostat treatment led to a dose- and time-dependent antiproliferative effect. Co-treatment of mocetinostat with radiation increased radiotherapy efficacy in co-cultures as well as in vivo. Potential genes associated with suppressed TM formation as well as radiosensitization were found through bulk RNA sequencing. Conclusions: With this drug testing and development pipeline, the HDACi mocetinostat was found to exhibit anti-TM effects in vitro and in vivo . Increased radiotherapy efficacy under mocetinostat support the concept of therapeutic tumor cell network disconnection, strengthening this avenue for novel neuroscience-instructed cancer therapies.
- 31 October 2026
- Published by Springer Nature in Cellular and Molecular Bioengineering
- p. 1-15
Open AccessMocetinostat Shows Network-Inhibitory Effects on Glioblastoma Cells, Enhancing Radiotherapy Efficacy
Purpose: Glioblastoma cells use neurite-like extensions, called tumor microtubes (TMs), as intercellular connections to integrate into a communicating network that contributes to glioblastoma’s high therapy resistance. Understanding the biological functions of tumor cell connectivity and overcoming network resistance has emerged as a new therapeutic opportunity. We tested histone deacetylase inhibitors (HDACi) regarding their potential to overcome TM-mediated connectivity and resistance to therapy in glioblastoma. Methods: To investigate HDACi, we applied a recently established drug testing pipeline consisting of mono- and co-culture of primary glioblastoma cells in vitro with simplified brain organoids readouts of TM parameters and tumor cell viability. Next, the effect of the class I HDACi mocetinostat in our in vivo two-photon microscopy model with radiotherapy as cytotoxic co-treatment was investigated. To understand underlaying molecular mechanisms, bulk RNA sequencing was performed. Results: Mocetinostat showed dose-dependent anti-TM effects in vitro , in contrast to other classes of HDACi in monoculture. In a co-culture of glioblastoma cells with cortical spheroids from human induced pluripotent stem cells, mocetinostat treatment led to a dose- and time-dependent antiproliferative effect. Co-treatment of mocetinostat with radiation increased radiotherapy efficacy in co-cultures as well as in vivo. Potential genes associated with suppressed TM formation as well as radiosensitization were found through bulk RNA sequencing. Conclusions: With this drug testing and development pipeline, the HDACi mocetinostat was found to exhibit anti-TM effects in vitro and in vivo . Increased radiotherapy efficacy under mocetinostat support the concept of therapeutic tumor cell network disconnection, strengthening this avenue for novel neuroscience-instructed cancer therapies.
- Open Access
- 27 March 2026
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 14
Psilocin fosters neuroplasticity in iPSC-derived human cortical neurons
Psilocybin is studied as innovative medication in anxiety, substance abuse and treatment-resistant depression. Animal studies show that psychedelics promote neuronal plasticity by strengthening synaptic responses and protein synthesis. However, the exact molecular and cellular changes induced by psilocybin in the human brain are not known. Here, we treated human cortical neurons derived from induced pluripotent stem cells with the 5-HT2A receptor agonist psilocin – the psychoactive metabolite of psilocybin. We analyzed how exposure to psilocin affects gene expression, neuronal morphology, synaptic markers and neuronal function. Psilocin provoked a 5-HT2A-R-mediated augmentation of BDNF abundance. Transcriptomic profiling identified gene expression signatures priming neurons to neuroplasticity. On a morphological level, psilocin induced enhanced neuronal complexity and increased expression of synaptic proteins, in particular in the postsynaptic compartment. Consistently, we observed an increased excitability and enhanced synaptic network activity in neurons treated with psilocin. In conclusion, exposure of human neurons to psilocin might induce a state of enhanced neuronal plasticity, which could explain why psilocin is beneficial in the treatment of neuropsychiatric disorders where synaptic dysfunctions are discussed.
- 27 March 2026
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 14
Open AccessPsilocin fosters neuroplasticity in iPSC-derived human cortical neurons
Psilocybin is studied as innovative medication in anxiety, substance abuse and treatment-resistant depression. Animal studies show that psychedelics promote neuronal plasticity by strengthening synaptic responses and protein synthesis. However, the exact molecular and cellular changes induced by psilocybin in the human brain are not known. Here, we treated human cortical neurons derived from induced pluripotent stem cells with the 5-HT2A receptor agonist psilocin – the psychoactive metabolite of psilocybin. We analyzed how exposure to psilocin affects gene expression, neuronal morphology, synaptic markers and neuronal function. Psilocin provoked a 5-HT2A-R-mediated augmentation of BDNF abundance. Transcriptomic profiling identified gene expression signatures priming neurons to neuroplasticity. On a morphological level, psilocin induced enhanced neuronal complexity and increased expression of synaptic proteins, in particular in the postsynaptic compartment. Consistently, we observed an increased excitability and enhanced synaptic network activity in neurons treated with psilocin. In conclusion, exposure of human neurons to psilocin might induce a state of enhanced neuronal plasticity, which could explain why psilocin is beneficial in the treatment of neuropsychiatric disorders where synaptic dysfunctions are discussed.
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Video 4 from Screening for Tumor Microtube–Targeting Drugs Identifies PKC Modulators as Multipotent Inhibitors of Glioblastoma Progression
Ca2+ imaging was performed on the 2DTM assay with tumor cells stained with Rhod-2AM Ca2+ sensor and visualized using live-cell confocal microscopy. Treatment with the PKC activator (TPPB, 1 μM) resulted in a marked reduction of global Ca2+ activity across the tumor cell network compared to the DMSO control
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video 4 from Screening for Tumor Microtube–Targeting Drugs Identifies PKC Modulators as Multipotent Inhibitors of Glioblastoma Progression
Ca2+ imaging was performed on the 2DTM assay with tumor cells stained with Rhod-2AM Ca2+ sensor and visualized using live-cell confocal microscopy. Treatment with the PKC activator (TPPB, 1 μM) resulted in a marked reduction of global Ca2+ activity across the tumor cell network compared to the DMSO control
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Video 6 from Screening for Tumor Microtube–Targeting Drugs Identifies PKC Modulators as Multipotent Inhibitors of Glioblastoma Progression
Live-cell confocal Ca2+ imaging of patient-derived glioblastoma cells (S24) within a hGliCS. Ca2+ dynamics were monitored using the Twitch Ca2+ reporter under DMSO control conditions. The video captures real-time Ca2+ activity within the hGliCS network
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video 6 from Screening for Tumor Microtube–Targeting Drugs Identifies PKC Modulators as Multipotent Inhibitors of Glioblastoma Progression
Live-cell confocal Ca2+ imaging of patient-derived glioblastoma cells (S24) within a hGliCS. Ca2+ dynamics were monitored using the Twitch Ca2+ reporter under DMSO control conditions. The video captures real-time Ca2+ activity within the hGliCS network
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Video 5 from Screening for Tumor Microtube–Targeting Drugs Identifies PKC Modulators as Multipotent Inhibitors of Glioblastoma Progression
In vivo multiphoton 3D volume of a S24 tumor growing in a mouse brain under a chronic cranial window, analyzed with the newly developed 3D morphometry pipeline. S24 GBSCs are green (GFP) and the predicted TMs and cell bodies can be visualized in different colors. Orthogonal planes are used to visualize the overlaps between the algorithm predictions and the raw data
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video 5 from Screening for Tumor Microtube–Targeting Drugs Identifies PKC Modulators as Multipotent Inhibitors of Glioblastoma Progression
In vivo multiphoton 3D volume of a S24 tumor growing in a mouse brain under a chronic cranial window, analyzed with the newly developed 3D morphometry pipeline. S24 GBSCs are green (GFP) and the predicted TMs and cell bodies can be visualized in different colors. Orthogonal planes are used to visualize the overlaps between the algorithm predictions and the raw data
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Video 3 from Screening for Tumor Microtube–Targeting Drugs Identifies PKC Modulators as Multipotent Inhibitors of Glioblastoma Progression
In vivo multiphoton imaging of tumor cell Ca2+ transients in awake mice, with tumors developing under a long-term cranial window (S24 GCaMP6 GBSCs)
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video 3 from Screening for Tumor Microtube–Targeting Drugs Identifies PKC Modulators as Multipotent Inhibitors of Glioblastoma Progression
In vivo multiphoton imaging of tumor cell Ca2+ transients in awake mice, with tumors developing under a long-term cranial window (S24 GCaMP6 GBSCs)
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Video 2 from Screening for Tumor Microtube–Targeting Drugs Identifies PKC Modulators as Multipotent Inhibitors of Glioblastoma Progression
Live cell confocal Ca2+ imaging of patient-derived GBSCs (S24) within a monolayer 2DTM in vitro assay. This assay fosters GBSC interconnection via TMs, resulting in a dense anatomical network with pronounced Ca2+ (co-)activity. Tumor cells are stained with the Rhod-2AM Ca2+ sensor
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video 2 from Screening for Tumor Microtube–Targeting Drugs Identifies PKC Modulators as Multipotent Inhibitors of Glioblastoma Progression
Live cell confocal Ca2+ imaging of patient-derived GBSCs (S24) within a monolayer 2DTM in vitro assay. This assay fosters GBSC interconnection via TMs, resulting in a dense anatomical network with pronounced Ca2+ (co-)activity. Tumor cells are stained with the Rhod-2AM Ca2+ sensor
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S26 from Screening for Tumor Microtube–Targeting Drugs Identifies PKC Modulators as Multipotent Inhibitors of Glioblastoma Progression
Supplementary Figures, Supplementary Figure Legends, and Supplementary Video Legends. Supplementary Figure S1: Stemness markers and in-vivo-like multicellular networks in the 2DTM growth assay. Supplementary Figure S2: Tumor cells do not form TMs and do not functionally interconnect under classical neurosphere conditions. Supplementary Figure S3: Development of a 2D morphometry pipeline for TM detection and quantification using ilastik software. Supplementary Figure S4: Ground truth TM annotations of S24, BG5 and T269 GBSCs cultured in 2DTM assay conditions. Supplementary Figure S5: Ground truth and Ilastik-based quantification of tumor cells and cell death via live-cell imaging. Supplementary Figure S6: Lead identification strategy for anti-TM drug classes. Supplementary Figure S7: Morphological disruption of BG5 and T269 GBSC TM-networks by PKC activators. Supplementary Figure S8: Basal and phosphorylation levels of PKC. Supplementary Figure S9: PKC activators disrupt TM network functionality. Supplementary Figure S10: AIVIA-based 3D Morphometry Pipeline. Supplementary Figure S11: Cell networks in a human glioblastoma-inbrain-spheroid (hGliCS) model. Supplementary Figure S12: Consequences of TPPB and PMA exposition in a human brain spheroid model. Supplementary Figure S13: Radioresistance of TM-connected vs TM-unconnected glioblastoma cells in an orthotopic mouse model. Supplementary Figure S14: In vivo drug testing pipeline. Supplementary Figure S15: In vivo evaluation of dynamic antitumor and anti-TM effects of short-term TPPB plus radiotherapy in the tumor cores. Supplementary Figure S16: In vivo antitumor and anti-TM effects in the tumor cores of individual mice having received combined radiotherapy and short-term TPPB administration. Supplementary Figure S17: Lunaphore COMETTM-based Ku80, MKI67 and cleaved Caspase-3 signal recognition and quantification in mice brains. Supplementary Figure S18: In vivo antitumor and anti-TM effects in the mouse cohort having received combined radiotherapy and long-term TPPB administration. Supplementary Figure S19: In vivo antitumor and anti-TM effects in individual mice having received combined radiotherapy and long-term TPPB administration. Supplementary Figure S20: Basal and phosphorylation levels of the known TM network drivers Cx43 and GAP43. Supplementary Figure S21: Global changes in gene expression after PKC activators treatments. Supplementary Figure S22: Gene expression changes per type of PKC modulating drug and GBSC. Supplementary Figure S23: Effects of the PKC activators TPPB and PMA on TTYH1, CHI3L1 and GAP43 RNA expression in GBSCs. Supplementary Figure S24: Anti-TM effects of TPPB on patient tumoroids. Supplementary Figure S25: Lunaphore COMETTM-based TTYH1 RNA recognition and quantification in mice brains. Supplementary Figure S26: Graphical summary. Multiple anti-tumor effects of TPPB in Glioblastoma.
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S26 from Screening for Tumor Microtube–Targeting Drugs Identifies PKC Modulators as Multipotent Inhibitors of Glioblastoma Progression
Supplementary Figures, Supplementary Figure Legends, and Supplementary Video Legends. Supplementary Figure S1: Stemness markers and in-vivo-like multicellular networks in the 2DTM growth assay. Supplementary Figure S2: Tumor cells do not form TMs and do not functionally interconnect under classical neurosphere conditions. Supplementary Figure S3: Development of a 2D morphometry pipeline for TM detection and quantification using ilastik software. Supplementary Figure S4: Ground truth TM annotations of S24, BG5 and T269 GBSCs cultured in 2DTM assay conditions. Supplementary Figure S5: Ground truth and Ilastik-based quantification of tumor cells and cell death via live-cell imaging. Supplementary Figure S6: Lead identification strategy for anti-TM drug classes. Supplementary Figure S7: Morphological disruption of BG5 and T269 GBSC TM-networks by PKC activators. Supplementary Figure S8: Basal and phosphorylation levels of PKC. Supplementary Figure S9: PKC activators disrupt TM network functionality. Supplementary Figure S10: AIVIA-based 3D Morphometry Pipeline. Supplementary Figure S11: Cell networks in a human glioblastoma-inbrain-spheroid (hGliCS) model. Supplementary Figure S12: Consequences of TPPB and PMA exposition in a human brain spheroid model. Supplementary Figure S13: Radioresistance of TM-connected vs TM-unconnected glioblastoma cells in an orthotopic mouse model. Supplementary Figure S14: In vivo drug testing pipeline. Supplementary Figure S15: In vivo evaluation of dynamic antitumor and anti-TM effects of short-term TPPB plus radiotherapy in the tumor cores. Supplementary Figure S16: In vivo antitumor and anti-TM effects in the tumor cores of individual mice having received combined radiotherapy and short-term TPPB administration. Supplementary Figure S17: Lunaphore COMETTM-based Ku80, MKI67 and cleaved Caspase-3 signal recognition and quantification in mice brains. Supplementary Figure S18: In vivo antitumor and anti-TM effects in the mouse cohort having received combined radiotherapy and long-term TPPB administration. Supplementary Figure S19: In vivo antitumor and anti-TM effects in individual mice having received combined radiotherapy and long-term TPPB administration. Supplementary Figure S20: Basal and phosphorylation levels of the known TM network drivers Cx43 and GAP43. Supplementary Figure S21: Global changes in gene expression after PKC activators treatments. Supplementary Figure S22: Gene expression changes per type of PKC modulating drug and GBSC. Supplementary Figure S23: Effects of the PKC activators TPPB and PMA on TTYH1, CHI3L1 and GAP43 RNA expression in GBSCs. Supplementary Figure S24: Anti-TM effects of TPPB on patient tumoroids. Supplementary Figure S25: Lunaphore COMETTM-based TTYH1 RNA recognition and quantification in mice brains. Supplementary Figure S26: Graphical summary. Multiple anti-tumor effects of TPPB in Glioblastoma.
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Video 1 from Screening for Tumor Microtube–Targeting Drugs Identifies PKC Modulators as Multipotent Inhibitors of Glioblastoma Progression
Live cell confocal recording of patient-derived GBSCs (S24), in classical neurosphere conditions where TMs and Ca2+ activity are not observed. Rhodamine-2 AM (Rhod-2AM) was used to track Ca2+ activity
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video 1 from Screening for Tumor Microtube–Targeting Drugs Identifies PKC Modulators as Multipotent Inhibitors of Glioblastoma Progression
Live cell confocal recording of patient-derived GBSCs (S24), in classical neurosphere conditions where TMs and Ca2+ activity are not observed. Rhodamine-2 AM (Rhod-2AM) was used to track Ca2+ activity
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S4 from Screening for Tumor Microtube–Targeting Drugs Identifies PKC Modulators as Multipotent Inhibitors of Glioblastoma Progression
Supplementary Table 1. This table provides the inventory of 43 features extracted from our customized ilastik workflow along with their respective categories and descriptions. Supplementary Table 2. List of potential 71 anti-TM compounds tested in our in vitro 2DTM assay. Supplementary Table 3. Concentrations used for the potential 71 anti-TM compounds tested in our in vitro 2DTM assay. Supplementary Table 4. Values of the fold change of Total TM length, TMs per cell, and percentage of dead cells after treatment with the 71 compounds.
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S4 from Screening for Tumor Microtube–Targeting Drugs Identifies PKC Modulators as Multipotent Inhibitors of Glioblastoma Progression
Supplementary Table 1. This table provides the inventory of 43 features extracted from our customized ilastik workflow along with their respective categories and descriptions. Supplementary Table 2. List of potential 71 anti-TM compounds tested in our in vitro 2DTM assay. Supplementary Table 3. Concentrations used for the potential 71 anti-TM compounds tested in our in vitro 2DTM assay. Supplementary Table 4. Values of the fold change of Total TM length, TMs per cell, and percentage of dead cells after treatment with the 71 compounds.